AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 51 min read$CORT

Lyon Joseph Douglas sold $1.2M of CORT

Lyon Joseph Douglas (See Remarks) sold 10,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.07 ($115.40–$116.54, $1.16M total) across 3 trades over 2026-10-01 to 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lyon Joseph Douglas
Published Oct 5, 2026, 11:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 11:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed sale is the primary new fact; no other material news is present.

02

Market read

A modest insider sale that may cause slight short‑term pressure on CORT.

03

What to watch

Potential upcoming dilution or secondary offering that prompted the insider to reduce holdings.

Relevance 5/10Novelty 3/10Timing: post‑market filing on Oct 5

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

Officer Lyon Joseph Douglas sold 10,000 shares for $1.16M via a 10b5‑1 plan.

Expected impact

likely modest downward pressure as the market prices the insider sale.

Evidence & confidence

A $1.2M sale by an officer is material but not large enough to drive a significant move; investors may view it as a neutral to slightly negative signal.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • Company
    Corcept Therapeutics Inc.

    Biopharma listed on NASDAQ under CORT.

  • Officer
    Lyon Joseph Douglas

    Insider reporting the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CORT insider trading history →

Related articles

SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min
SEP 19
$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

stocktwits.com2 min
SEP 18
$CORTHighAI 9/10

Corcept Therapeutics Incorporated: Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)

Corcept Therapeutics (CORT) announced the European Medicines Agency's CHMP recommended EU approval for relacorilant, combined with nab-paclitaxel, to treat platinum-resistant ovarian cancer. The recommendation follows positive Phase 2 and Phase 3 trial results showing improved survival rates. The EC will decide by Q4 2026. Relacorilant is already FDA-approved in the U.S. for the same indication.

finanznachrichten.de2 min
AUG 6
$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

yahoo.com3 min
JUL 31
$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min